A REVIEW ON THE ROLE OF TRIGLYCERIDE IN METABOLIC SYNDROME

ABDOLJALAL MARJANI*

Department of Biochemistry and Biophysics, Metabolic Disorders Research Center, Gorgan Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Golestan Province, Iran. Email: abdoljalal@yahoo.com

ABSTRACT

Increased serum triglyceride levels are commonly observed in subjects with metabolic syndrome (MS). Many studies show that hypertriglyceridemia is forcefully collaborated with all components of MS. The aim of this study was to review the role of triglyceride in MS. Based on prior epidemiological studies, this review indicates association of high triglyceride levels with cardiovascular disease (CVD). On the other hand, it is clearly shown that CVD is one of the main causes of death worldwide. Thus, it is important to investigate about MS and its components to decrease the prevalence of MS among different.

Keywords: Triglycerides, Risk factors, Metabolic syndrome, Cardiovascular disease.

INTRODUCTION

There is an elevated attention on metabolic syndrome (MS) in the past few years. MS was defined by Reaven as a conglomerate of coronary risk factors, in 1998 [1]. Many other researchers have shown modified definitions [2-4]. In 2007, Grundy [5] explained the reasons for MS analysis, which were more useful than the clinical perspective. Detection of MS is important. MS can be identified with the risk of atherosclerosis, Type 2 diabetes mellitus (T2DM), morbidities and mortality [6-13]. The prevalence of MS differs according to different factors, i.e. country, gender, and age. The prevalence of MS depends on age progression. In fact, some studies have shown different rates of MS prevalence in the world [14]. Age-depended studies on people of some European countries (Switzerland, Spain, the Netherlands, Italy, France, the UK, and Denmark) showed that the prevalence of MS changed from 14% to 41% in non-diabetic individuals under 40 years old [14]. Buckland et al. [15] showed that the frequency of MS in people of Catalonia (Spain), aged 18-74 years elevated from 2.5% to 51.1%. Ford et al. [16] also revealed that the prevalence of MS in people of USA altered from 6.7% (20-29 years old) to 43.5% (60-69 years old). Different cross-sectional studies have shown that the prevalence of MS in some developing countries is high. Studies on adult Indian and Iranian people indicated that the prevalence of MS changed from 33.7% to 41% [17-19]. It is noteworthy to mention that Marjani et al. showed that the most age distributions of this disease were between ages of 35 and 40 years and the frequency of MS reached its peak in ages of 35-40 years. The same study also represented the increased frequency of MS within Fars women aged 25-29 [20]. However, some studies in Turkey and Norway demonstrated that the prevalence of the MS increased with age [21,22]. Cardiovascular diseases (CVDs) are one of the main causes of death among females in the world [23]. Many studies have shown that females aged over 55 pose a higher risk of developing CVD than younger females [24-26]. Dyslipidemia is described as high triglyceride and low high-density lipoprotein (HDL) cholesterol levels in MS. Elevated free fatty acids cause hypertriglyceridemia in people with insulin resistance and hyperinsulinemia. Hypertriglyceridemia is collaborated with modification in HDL and LDL structure and metabolism [27]. Increased serum triglyceride levels are frequently observed in subjects with MS. Many studies showed that hypertriglyceridemia is forcefully collaborated with all components of MS. Patients with MS and high triglyceride in many cases show increased atherogenic level of triglyceride-rich lipoproteins [27]. There are still different controversial questions that whether high triglyceride is the reason of coronary artery disease or not. Many studies have shown that hypertriglyceridemia collaborated with elevated coronary disease risk in both genders [28]. It has been reported that the prevalence of hypertriacylglycerolemia was more prevalent in males than in females 12.9% and 16.7% respectively [29,30] whiles study of Velásquez-Meléndez et al. [31] indicated that this trend was partly higher in females (23.9%) than males (20.5%). There were significant differences between the mean values of triglyceride among women with and without MS in age groups 20-24, 25-29, 30-34, and 35-40 years old [32]. Some studies have reported that the prevalence of high triglyceride levels was considered in women with MS in different ethnic groups [20,33-35]. People in India, Pakistan, Sri Lanka, Bangladesh, and Nepal have shown an increased prevalence of MS and T2DM when compared with Europeans [36]. Several factors such as increased fat compared with muscle tissue and central body fat distribution, have been suggested to explain the tendency of South Asians to develop these metabolic risk factors for CVD [37]. Studies in American Indians on triglyceride levels regarding the influence of MS and T2DM have shown that a moderate elevation in triglyceride levels and a significant increase in prevalence of T2DM have contributed to incident CVD [38,39]. It has been indicated that non-fasting triglyceride levels were associated with incident of CVD, elevated risk of myocardial infarction, ischemic heart disease and death [40,41]. The aim of the present study was to review on triglyceride in MS.

TRIGLYCERIDES AND DISEASE RISK

The differences in the prevalence of MS, with respect to the components of MS have been shown. These differences might be described by genetic, environmental, and socio-demographic factors in different countries and populations [42].

The slope of morbidity and mortality because of MS has changed in recent decades due to exchanges in food intake, lifestyle habits, and reduction in physical activity among the different population in the world. Many epidemiological researches have shown the connection between triglycerides and coronary heart disease (CHD) risk, but the association had not been determined clearly [43]. Another study [44] clearly demonstrated the relation of fasting triglycerides and alterations in fasting triglycerides with the incidence of CHD in Israeli soldiers aged 26-45 years. Most population studies showed an association between fasting plasma triglycerides and CVD risk in addition that triglyceride was no longer an independent predictor [45-47], while other studies showed that triglyceride maintained its independent predictive power [48]. Study of Austin [49] indicated that underrating of triglyceride association with CHD is due to the fact of the biological

differences in its measurement and an inverse correlation between triglycerides and HDL-cholesterol, making multivariable estimation of its effect difficult to explain.

The study on healthy American women showed that fasting and non-fasting triglycerides were associated with future CVD after adjustments for age, blood pressure, smoking, and hormone-replacement therapy [40]. Studies on Japanese men and women has been shown that non-fasting triglyceride has revealed associated with increased CVD risk and also another study reported that non-fasting triglyceride was a stronger predictor of CVD than fasting triglycerides [50].

The prevalence of triglyceride levels higher than 150 mg/dL is almost twice higher in subjects with MS compared to those without MS [51,52]. High triglyceride level was the second most common (74%) among components of MS [53]. Observation of high prevalence of triglyceride levels have shown in patients with MS and CVD [54]. Studies showed that there are associations between patients with chronic kidney disease (CKD) and dyslipidemia. It takes place in patients with nephrotic syndrome, in patients undergoing dialysis, and after renal transplantation [55]. A triglyceride level higher than 200 mg/dL has been shown in almost 50% of patients with CKD. Several risk factors such as T2DM, obesity, and infrared change lipoprotein metabolism. MS, often are seen in CKD patients [56].

CONCLUSION

This review is about the possible correlation of high triglyceride levels with CVD and indicates their close association based on prior epidemiological studies. Therefore, it is highly recommended to further investigate their association to decrease the prevalence of morbidity and mortality caused by CVDs.

REFERENCES

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37(12):1595-607.
2. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005;111(11):1448-54.
3. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, *et al.* Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112(17):2735-52.
4. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – A new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23(5):469-80.
5. Grundy SM. Metabolic syndrome: A multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007;92(2):399-404.
6. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, *et al.* Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
7. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009;2(5-6):231-7.
8. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, *et al.* The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288(21):2709-16.
9. Maggi S, Noale M, Gallina P, Bianchi D, Marzari C, Limongi F, *et al.* Metabolic syndrome, diabetes, and cardiovascular disease in an elderly Caucasian cohort: The Italian Longitudinal Study on Aging. J Gerontol A Biol Sci Med Sci 2006;61:505-10.
10. Bataille V, Perret B, Dallongeville J, Arveiler D, Yarnell J, Ducimetière P, *et al.* Metabolic syndrome and coronary heart disease risk in a population-based study of middle-aged men from France and Northern Ireland. A nested case-control study from the Prime cohort. Diabetes Metab 2006;32(5 Pt 1):475-9.
11. Pischon T, Hu FB, Rexrode KM, Girman CJ, Manson JE, Rimm EB. Inflammation, the metabolic syndrome, and risk of coronary heart disease in women and men. Atherosclerosis 2008;197(1):392-9.
12. Taslim S, Tai ES. The relevance of the metabolic syndrome. Ann Acad Med Singapore 2009;38(1):29-5.
13. Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005;165(22):2644-50.
14. Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, *et al.* Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28:364-76.
15. Buckland G, Salas-Salvadó J, Roure E, Bulló M, Serra-Majem L. Sociodemographic risk factors associated with metabolic syndrome in a Mediterranean population. Public Health Nutr 2008;11(12):1372-8.
16. Ford ES, Mokdad AH, Giles WH, Mensah GA. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: Findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 2003;107(17):2185-9.
17. Azizi F, Salehi P, Etemadi A, Zahedi-Asl S. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res Clin Pract 2003;61(1):29-37.
18. Delavari A, Forouzanfar MH, Alikhani S, Sharifian A, Kelishadi R. First nationwide study of the prevalence of the metabolic syndrome and optimal cutoff points of waist circumference in the Middle East: The national survey of risk factors for noncommunicable diseases of Iran. Diabetes Care 2009;32(6):1092-7.
19. Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Metabolic syndrome in urban Asian Indian adults – A population study using modified ATP III criteria. Diabetes Res Clin Pract 2003;60(3):199-204.
20. Marjani A, Hezarkhani S, Shahini N. Prevalence of metabolic syndrome among Fars ethnic women in North East of Iran. World J Med Sci 2012;7(1):17-22.
21. Sanisoglu SY, Oktenli C, Hasimi A, Yokusoglu M, Ugurlu M. Prevalence of metabolic syndrome-related disorders in a large adult population in Turkey. BMC Public Health 2006;6:92.
22. Hildrum B, Mykletun A, Hole T, Midthjell K, Dahl AA. Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: The Norwegian HUNT 2 study. BMC Public Health 2007;7:220.
23. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, *et al.* Heart disease and stroke statistics--2009 update: A report from the American heart association statistics committee and stroke statistics subcommittee. Circulation 2009;119(3):480-6.
24. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third national health and nutrition examination survey. JAMA 2002;287(3):356-9.
25. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population. Am Heart J 1986;111(2):383-90.
26. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, *et al.* Heart disease and stroke statistics--2007 update: A report from the American heart association statistics committee and stroke statistics subcommittee. Circulation 2007;115:e69-171.
27. Menuet R, Lavie CJ, Milani RV. Importance and management of dyslipidemia in the metabolic syndrome. Am J Med Sci 2005;330(6):295-302.
28. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3(2):213-9.
29. Pérez CM, Guzmán M, Ortiz AP, Estrella M, Valle Y, Pérez N, *et al.* Prevalence of the metabolic syndrome in San Juan, Puerto Rico. Ethn Dis 2008;18(4):434-41.
30. Medina-Lezama J, Zea-Diaz H, Morey-Vargas OL, Bolaños-Salazar JF, Muñoz-Atahualpa E, Postigo-MacDowall M, *et al.* Prevalence of the metabolic syndrome in Peruvian Andean Hispanics: The prevencion study. Diabetes Res Clin Pract 2007;78(2):270-81.
31. Velásquez-Meléndez G, Gazzinelli A, Côrrea-Oliveira R, Pimenta AM, Kac G. Prevalence of metabolic syndrome in a rural area of Brazil. Sao Paulo Med J 2007;125(3):155-62.
32. Marjani A, Shahini N. Age related metabolic syndrome among Fars ethnic women in Gorgan, Iran. J Pharm Biomed Sci 2013;30(30):929-35.
33. Shahini N, Shahini I, Marjani A. Prevalence of metabolic syndrome in Turkmen ethnic groups in Gorgan. J Clin Diagn Res 2013;7(9):1849-51.
34. Marjani A, Shahini N, Atabay OA, Tabari RG. Prevalence of metabolic syndrome among Sistanee ethnic women. Adv Stud Biol 2012;4(8):363-72.
35. Marjani A, Moghasemi S. The metabolic syndrome among postmenopausal women in Gorgan. Int J Endocrinol 2012;2012:953627.

36. Forouhi NG, Sattar N. CVD risk factors and ethnicity – A homogeneous relationship? Atheroscler Suppl 2006;7(1):11-9.

37. Bainey KR, Jugdutt BI. Increased burden of coronary artery disease in South-Asians living in North America. Need for an aggressive management algorithm. Atherosclerosis 2009;204(1):1-10.

38. Howard BV, Lee ET, Cowan LD, Fabsitz RR, Howard WJ, Oopik AJ, *et al.* Coronary heart disease prevalence and its relation to risk factors in American Indians. The Strong Heart Study. Am J Epidemiol 1995;142(3):254-68.

39. Howard BV, Lee ET, Cowan LD, Devereux RB, Galloway JM, Go OT, *et al.* Rising tide of cardiovascular disease in American Indians. The Strong Heart Study. Circulation 1999;99(18):2389-95.

40. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298(3):309-16.

41. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298(3):299-308.

42. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: Prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004;33(2):351-75.

43. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, *et al.* Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115(4):450-8.

44. Tirosh A, Rudich A, Shochat T, Tekes-Manova D, Israeli E, Henkin Y, *et al.* Changes in triglyceride levels and risk for coronary heart disease in young men. Ann Intern Med 2007;147(6):377-85.

45. Albrink MJ, Man EB. Serum triglycerides in coronary artery disease. AMA Arch Intern Med 1959;103(1):4-8.

46. Fager G, Wiklund O, Olofsson SO, Wilhelmsen L, Bondjers G. Multivariate analyses of serum apolipoproteins and risk factors in relation to acute myocardial infarction. Arteriosclerosis 1981;1(4):273-9.

47. Goldstein JL, Hazzard WR, Schrott HG, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J Clin Invest 1973;52(7):1533-43.

48. Bainton D, Miller NE, Bolton CH, Yarnell JW, Sweetnam PM, Baker IA, *et al.* Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Br Heart J 1992;68:60-6.

49. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991;11(1):2-14.

50. Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, *et al.* Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 2004;110(17):2678-86.

51. Schwartz GG, Olsson AG, Szarek M, Sasiela WJ. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: An analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care 2005;28:2508-13.

52. Suzuki T, Katz R, Jenny NS, Zakai NA, LeWinter MM, Barzilay JI, *et al.* Metabolic syndrome, inflammation, and incident heart failure in the elderly: The cardiovascular health study. Circ Heart Fail 2008;1(4):242-8.

53. Kasai T, Miyauchi K, Kurata T, Ohta H, Okazaki S, Miyazaki T, *et al.* Prognostic value of the metabolic syndrome for long-term outcomes in patients undergoing percutaneous coronary intervention. Circ J 2006;70(12):1531-7.

54. Anderson JL, Horne BD, Jones HU, Reyna SP, Carlquist JF, Bair TL, *et al.* Which features of the metabolic syndrome predict the prevalence and clinical outcomes of angiographic coronary artery disease? Cardiology 2004;101(4):185-93.

55. Saland JM, Ginsberg HN. Lipoprotein metabolism in chronic renal insufficiency. Pediatr Nephrol 2007;22(8):1095-112.

56. Tsimihodimos V, Dounousi E, Siamopoulos KC. Dyslipidemia in chronic kidney disease: An approach to pathogenesis and treatment. Am J Nephrol 2008;28(6):958-73.